A comparison of isobutyl 2-cyanoacrylate glue, fibrin adhesive, and oxidized regenerated cellulose for control of needle hole bleeding from polytetrafluoroethylene vascular prostheses.
Prolonged anastomotic and needle hole bleeding from synthetic vascular prostheses is a common surgical problem in heparinized patients and in the patient with a coagulopathy. The relative effectiveness of various hemostatic agents has not previously been determined by controlled comparisons. In this study 6 mm polytetrafluoroethylene (PTFE) vascular prostheses were used to perform carotid-carotid and femorofemoral bypasses in eight heparinized dogs. The relative effectiveness of isobutyl 2-cyanoacrylate, fibrin adhesive, and oxidized regenerated cellulose was determined by application of these hemostatic agents to three sources of bleeding: arterial-PTFE anastomoses, PTFE-PTFE anastomoses, and 18-gauge needle holes in PTFE vascular prostheses. The mean time to hemostasis (MTH) was determined for each hemostatic agent. Although application of isobutyl 2-cyanoacrylate resulted in the shortest MTH in each experimental group, the reported inflammatory response that it induces and its possible carcinogenicity limits its availability for clinical use. Application of fibrin adhesive prepared from single-donor hepatitis-screened plasma resulted in a significantly shorter MTH in each experimental group when compared with oxidized regenerated cellulose. We recommend clinical use of fibrin adhesive to control needle hole and anastomotic bleeding from PTFE vascular prostheses.
D000818:Animals; D007611:Aprotinin / Q000627:therapeutic use*; D001807:Blood Vessel Prosthesis; D002482:Cellulose / Q000031:analogs & derivatives*; D002483:Cellulose, Oxidized / Q000627:therapeutic use*; D003487:Cyanoacrylates / Q000627:therapeutic use*; D004285:Dogs; D004338:Drug Combinations / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005176:Factor XIII / Q000627:therapeutic use*; D015718:Fibrin Tissue Adhesive; D005340:Fibrinogen / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects; D006490:Hemostatics / Q000627:therapeutic use*; D009339:Needles; D011138:Polytetrafluoroethylene; D011183:Postoperative Complications / Q000188:drug therapy*; D013917:Thrombin / Q000627:therapeutic use*; D013997:Time Factors
D002483:Cellulose, Oxidized; D003487:Cyanoacrylates; D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D006490:Hemostatics; D005340:Fibrinogen; D011138:Polytetrafluoroethylene; D002482:Cellulose; D005176:Factor XIII; D007611:Aprotinin; D013917:Thrombin